Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
09/22/20169:38AMBWBristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Leerink Partners Immuno-Oncology Roundtable Conference on Thursday, September 29, 2016, in New York. Fouad Namouni, senior vice president, Head of Oncology, will answer questions about the company at 3:00 p.m. EDT. Investors and the general public are invited to... More...>>
09/20/20166:59AMBWEuropean Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Advanced...
Results from Phase 2 study CheckMate -275 evaluating Opdivo in metastatic urothelial carcinoma serve as basis for application Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the current indications for Opdivo... More...>>
09/20/20166:59AMBWBristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio
Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher and Suono Bio are the winners of Bristol-Myers Squibb’s Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers... More...>>
09/07/201611:17AMBWBristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016. During a conference call at 10:30 a.m. EDT on October 27, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public... More...>>
09/07/201610:41AMBWBristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch Global Health Care Conference on Wednesday, September 14, 2016, in London. John Elicker, senior vice president, Public Affairs and Investor Relations, will make a formal presentation about the company at 1 p.m. BST (8 a.m. EDT). Investors... More...>>
09/07/20166:59AMBWBristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research
For the third consecutive year, teams of Bristol-Myers Squibb employees will cycle across the U.S. in the Coast 2 Coast 4 Cancer Ride to raise donations in support of Stand Up To Cancer’s efforts to accelerate research Bristol-Myers Squibb will match money raised, dollar-for-dollar, up to $500,000 Today, the first of... More...>>
09/06/201612:14PMBWBristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2016 Global Health Care Conference on Tuesday, September 13, 2016, in New York. Giovanni Caforio, M.D., chief executive officer will make formal remarks about the company and answer questions at 11:10 a.m. EDT. Investors and the general public... More...>>
09/06/20166:59AMBWEuropean Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active & Progressive ...
ORENCIA is the first biologic therapy with an EU indication specifically applicable to the treatment of MTX-naive RA patients with highly active and progressive disease This approval marks the first time that MRI assessment of structural and inflammatory measures of disease severity are cited in SmPC to support an RA indication... More...>>
08/31/20167:05PMBWBristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights
Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference on Sunday, October 9, 2016, at 7:30 p.m. CEST (1:30 p.m. EDT) to discuss data presented at the European Society of Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. Company executives will provide an overview of data presented at the meeting... More...>>
08/23/20166:59AMBWBristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016
Nineteen abstracts to be presented, including new post-hoc sub-analyses from the ARISTOTLE Phase 3 trial and multiple retrospective real-world data analyses from ACROPOLIS Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations... More...>>
08/11/20163:04AMDJNBusiness Watch -- WSJ
SAMSUNG GROUP Drug Unit Plans $2.5 Billion IPO Samsung BioLogics Co., the contract drug-manufacturing unit of South Korean conglomerate Samsung Group, is planning to raise as much as $2.5 billion from an initial public offering that would value it at roughly $10 billion, according to people familiar with the matter. The... More...>>
08/10/20164:10AMDJNSamsung BioLogics Aims to Raise Up to $2.5 Billion From IPO
Samsung BioLogics Co., the contract drug manufacturing unit of South Korean conglomerate Samsung Group, is planning to raise as much as $2.5 billion from an initial public offering that would value it at roughly $10 billion, according to people familiar with the matter. The company, which manufactures complex biologic... More...>>
08/05/201611:43PMDJNWhat's News: Business & Finance
The U.S. labor market in July capped the best two-month stretch of hiring so far this year despite global turbulence and slower business spending, posing a challenge for the Fed. The Nasdaq rose to a record, signaling renewed appetite for risk. The S&P 500 also closed at a high. The Dow gained 191.48 points. A cancer... More...>>
08/05/201612:58PMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--4th Update
By Peter Loftus, Jonathan D. Rockoff and Anne Steele In a surprise finding that raises questions about the potential for a new class of cancer drugs that harness the body's immune system, Bristol-Myers Squibb Co. said its drug Opdivo wasn't significantly better than chemotherapy in a study of patients with newly... More...>>
08/05/201610:36AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--3rd Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.21 in early trading, erasing roughly $22 billion of the company's market value and... More...>>
08/05/201610:15AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--2nd Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 16% to $63.07 in early trading. Meanwhile, shares of Merck & Co. rose 5.6% as the result suggests... More...>>
08/05/20169:39AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 19% to $61 in premarket trading. Meanwhile, shares of Merck & Co. rose 11% as the results suggest... More...>>
08/05/20169:20AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study
Bristol-Myers Squibb Co. said results for a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.60 in premarket trading. Meanwhile, shares of Merck & Co. rose 10% as the results suggest... More...>>
08/05/20169:12AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study
By Anne Steele Bristol-Myers Squibb Co. said results for a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.60 in premarket trading. Meanwhile, shares of Merck & Co. rose 10% as the... More...>>
08/05/20168:20AMBWBristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïv...
Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing PD-L1 ≥ 5% Bristol-Myers Squibb Company (NYSE:BMY) announced today that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20160927 01:55:53